Dan Mendelson
Showing 1–2 of 2 transcripts.
- Milken Institute59 min
Finding a Cure for the Cost of Durable Therapies
Dan Mendelson, Yvonne Greenstreet, Joe Grogan, Michael Sherman, Mark Skinner, John Birch, Ian Kramer, Jupiter Lazmar
A panel of industry leaders, payers, and advocates highlighted the systemic friction between transformative gene therapies and traditional commercial models that rely on high-volume patient pools to amortize R&D costs. Participants detailed pricing pressures for one-time cures and chronic durable treatments while showcasing innovative risk-sharing agreements, such as Alnylam's outcomes-based pilot with Harvard Pilgrim Health Care, to manage financial exposure. Addressing these challenges, the group called for federal policy reform to eliminate "best price" disincentives and the adoption of flexible valuation frameworks that integrate patient-reported outcomes to prevent insurance affordability crises.
- Milken Institute1h 2m
New Players Disrupting the Healthcare and R&D Landscape
Dan Mendelson, Marc Harrison, Thomas Moriarty, Mario Schlosser, Benjamin Seet, Sue Siegel, David Freeman, Jr., Margot Sanger
Industry leaders from Intermountain Healthcare, CVS Health, Oscar Health, ASTAR, and GE Health converge to address the unsustainable trajectory of U.S. and global healthcare costs through a strategic shift from volume-based to value-driven payment models. The discussion highlights critical initiatives including Intermountain's standalone generic drug venture, CVS's integration of pharmacists into community care hubs, and Oscar's full-stack technology infrastructure designed to leverage telemedicine for acute condition management. While these organizations and non-traditional entrants like Amazon and tech giants in Asia drive innovation, they simultaneously navigate systemic barriers such as data interoperability failures, consumer financial toxicity, and the complex challenge of scaling digital adoption across diverse demographics.